AKERO THEREP.INC.DL-0001 (0K4 F) stock market data APIs
€46.487
0(0%)
as of November 6, 2025
Try our APIs with
free plan!
AKERO THEREP.INC.DL-0001 Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
46.487
Open
46.487
High
46.487
Low
46.487
52 wk Range
21.19-55.1
Market Cap
3 736 M
Shares Outstanding
80 165 K
Beta
-0.409
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AKERO THEREP.INC.DL-0001 data using free add-ons & libraries
Get AKERO THEREP.INC.DL-0001 Fundamental Data
AKERO THEREP.INC.DL-0001 Fundamental data includes:
- Net Revenue:
- EBITDA: -321 457 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -0.93
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AKERO THEREP.INC.DL-0001 News
New
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
Novo Nordisk A/S Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased by 5% in Danish kroner and 10% at constant exchange rate...
Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera. Continue Reading Afficher les commentaires
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
SynOx Therapeutics Limited Charles “Chip” Romp and Tom Heyman join SynOx’s Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generatio...
Assessing Akero Therapeutics (AKRO) Valuation After Strong Share Price Gains
Akero Therapeutics (AKRO) shares have delivered sizable gains for investors over the past year, with the stock up roughly 72%. Lately, its performance has piqued interest because of strong month and y...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
